These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26123794)

  • 1. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
    Scott LM; Gandhi MK
    Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Benson KL; Mesa RA
    Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
    Keohane C; Mesa R; Harrison C
    Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
    Derenzini E; Younes A
    Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 inhibitors and their impact in myeloproliferative neoplasms.
    Geyer HL; Tibes R; Mesa RA
    Hematology; 2012 Apr; 17 Suppl 1():S129-32. PubMed ID: 22507800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
    Quintás-Cardama A; Verstovsek S
    Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future status of JAK inhibitors.
    McLornan DP; Pope JE; Gotlib J; Harrison CN
    Lancet; 2021 Aug; 398(10302):803-816. PubMed ID: 34454676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review of pacritinib in myelofibrosis.
    Verstovsek S; Komrokji RS
    Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
    Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
    Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
    Santos FP; Verstovsek S
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.